Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

On April 21, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, reported that its abstract has been accepted for online publication at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This marks Akari’s first abstract acceptance at ASCO (Free ASCO Whitepaper), one of the most highly regarded forums in clinical oncology research, and represents a significant milestone for the Company as it continues to advance its AKTX-101 ADC into Phase 1 clinical development by late 2026/early 2027.
Details are as follows:

Abstract Title: Combination synergy of spliceosome modulator ADC with a K-Ras inhibitor in KRAS–mutated pancreatic cancers

Date and Time: The full publication will be made available on May 21, 2026, at 5:00 PM ET on the ASCO (Free ASCO Whitepaper) website.

"This first ASCO (Free ASCO Whitepaper) acceptance for Akari is continued validation of our novel RNA splicing modulator payload platform for ADCs, and its broad potential in treating a wide range of cancer tumors, including those with KRAS mutations, a rapidly expanding therapeutic category moving forward," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "We believe this data highlights a growing body of evidence demonstrating that targeting RNA splicing in cancer cells could be a powerful way to attack even the most difficult cancers."

Additional details will be disclosed in accordance with ASCO (Free ASCO Whitepaper) embargo policies.

For more information about the ASCO (Free ASCO Whitepaper) Annual Meeting 2026, please visit asco.org.

(Press release, Akari Therapeutics, APR 21, 2026, View Source [SID1234664594])

FDA confirms path to DEP® HER2
first-in-human study

On April 21, 2026 Starpharma (ASX: SPL, US OTC: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, reported that the company has met with the United States Food and Drug Administration (US FDA) in a Type C guidance meeting and received positive feedback on the proposed clinical development strategy and design of the first-in-human (FIH) phase 1 clinical study for its DEP HER2 radiotherapy candidate ("DEP HER21").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DEP HER2 is a HER2 receptor-targeting dendrimer conjugate with a lutetium-177 radionuclide payload. Starpharma is developing DEP HER2 for the treatment of locally advanced or metastatic HER2-overexpressing gastric/gastro-oesophageal junction cancers and other HER2 expressing advanced cancers in patients who have received prior HER2-targeted therapy.

Key highlights for investors

• FDA alignment on FIH phase 1 study design and overall clinical development approach for DEP HER2
• FDA feedback supports plans to initiate the FIH phase 1 study
• FDA confirms that patients with advanced HER2-expressing cancers who have exhausted available HER2-directed therapies represent a population with significant unmet medical need
• FIH phase 1 study remains on track to enter the clinic in H2 CY 2026

Unmet need

Overexpression of HER2 is a key driver in aggressive breast and gastric cancers, and there are limited treatment options available to patients after progression, resistance, or toxicity from current HER2-directed therapies. Starpharma is developing DEP HER2 to address these clinical challenges.

The FDA confirmed that patients with advanced HER2-expressing cancers who have exhausted available HER2-directed therapies represent a population with significant unmet medical need, meaning that there is potential to pursue Fast Track designation and other accelerated development pathways for DEP HER2 in the future.

Clinical pathway

Starpharma plans to conduct a FIH phase 1 study in Europe initially in up to 15 patients to evaluate safety and tolerability, and to characterise pharmacokinetics, biodistribution and organ radiation dosimetry of DEP HER2 in patients with advanced HER2-positive cancers.

The FDA confirmed that the clinical data generated outside of the US, together with the currently available DEP HER2 preclinical data package, including a recently completed formal toxicology study, should be adequate to support future US-based clinical studies under an Investigational New Drug (IND) application.

The FDA provided clear guidance on chemistry, manufacturing and controls (CMC) expectations for DEP HER2, and agreed with Starpharma’s current approach to the manufacture and characterisation of Starpharma’s novel dendrimer-based radioligand therapy.

Professor Tony Lahoutte, MD, PhD, a physician and Head of the Department of Nuclear Medicine at University Hospital (UZ) Brussel, and Head of Molecular Imaging and Therapy Research (MITH) at the Vrije Universiteit Brussel (VUB) in Belgium, advised Starpharma on the DEP HER2 radiotherapy clinical development strategy. He attended the FDA meeting as a representative of Starpharma, contributing expert clinical nuclear medicine input to the discussion of our radiopharmaceutical study design.

Following the meeting with the FDA, Prof. Lahoutte commented:

"The FDA’s feedback provides important confirmation that Starpharma’s first-in-human phase 1 design and overall clinical strategy for DEP HER2 are in line with regulatory expectations. From a nuclear medicine and radiopharmaceutical perspective, the proposed approach to patient selection, dosimetry and safety evaluation is appropriate. DEP HER2 combines a HER2-targeting moiety with Starpharma’s novel, dendrimer-based delivery platform. The planned clinical study is well positioned to demonstrate the benefit of the dendrimer technology in targeted radioligand therapy, and to support further clinical development of the product for this high unmet-need population with HER2-expressing cancers."

Next steps

Starpharma is currently undertaking the activities required to commence the FIH phase 1 study and remains on track to begin in H2 CY 2026. Clinical site selection is complete, and the company is progressing radiopharmacy preparations, site onboarding and required ethics and regulatory approvals.

Cheryl Maley, Starpharma’s Chief Executive Officer, commented:

"DEP HER2 is a key strategic asset for Starpharma, supported by comprehensive preclinical data and a clinically validated platform technology. We are particularly excited by the encouraging data generated to date, which have shown important benefits in targeted delivery for radiotherapeutics.

"This FDA feedback is an important milestone, providing regulatory clarity and validation for the proposed clinical development pathway and marking the exciting transition from preclinical to clinical development. The guidance provides confidence that our current preclinical package, together with the data generated in the forthcoming first-in-patient study, would support a subsequent IND application and clinical development in the US. "

By exemplifying the value of DEP technology in the high-growth area of radiotherapy in a clinical setting, Starpharma aims to broaden the therapeutic applications and commercial opportunities of its dendrimer platform, whilst continuing to deliver meaningful outcomes for patients."

(Press release, Starpharma, APR 21, 2026, View Source [SID1234664556])

Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor Immunotherapy

On April 20, 2026 Enara Bio, a pioneer in Dark Antigen discovery and bispecific T cell engager (TCE) innovation, reported the presentation of new preclinical data for ENA101, its first‑in‑class bispecific T cell engager (TCE), delivered today in an oral session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ENA101 targets DARKFOX, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT platform and represents a new class of highly tumor‑specific targets derived from the dark proteome.

"ENA101 exemplifies the power of uncovering antigens within the dark proteome to overcome long-standing challenges in solid tumor immunotherapy," said Dr. Joe Dukes, Chief Scientific Officer of Enara Bio. "The data presented today at AACR (Free AACR Whitepaper) demonstrate that DARKFOX is a compelling cancer specific target and that ENA101 exhibits the potency, specificity and druglike profile required to advance a best-in-class T cell engager toward the clinic."

The oral presentation, titled "ENA101: A First‑in‑Class Bispecific T Cell Engager Targeting a DARKFOX Peptide Presented by Solid Tumors," was delivered by Dr. Joe Dukes in the Advances in Therapeutic Antibodies session
(Abstract #4052). The presentation highlighted the discovery of DARKFOX, the engineering of ENA101, and the comprehensive preclinical dataset supporting its advancement into clinical development.

Enara Bio is currently advancing ENA101 through IND-enabling studies to support IND filing in 2H’2026.

The abstract is available in Proceedings of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026.

About ENA101
ENA101 is a first‑in‑class bispecific T cell engager developed using Enara Bio’s proprietary EnTiCE platform. It incorporates a high‑affinity TCR‑mimic binder targeting the DARKFOX‑A3 peptide, a clinically validated anti‑CD3 arm, and an Fc‑based architecture for half‑life extension, to enable potent, selective and durable anti‑tumor immune responses.

(Press release, Enara Bio, APR 20, 2026, View Source [SID1234664592])

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

On April 20, 2026 Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, reported updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) as part of a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026. [212Pb]VMT-α-NET is potentially the first-in-class 212Pb-radiopharmaceutical therapy targeting SSTR2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interim results with a data cut-off date of March 4, 2026 formed the basis of the AACR (Free AACR Whitepaper) update. The presentation includes safety data from 64 patients across three dose cohorts who have received at least one treatment of [212Pb]VMT-α-NET, and efficacy analysis from two patients in Cohort 1 (2.5 mCi) and 23 patients in Cohort 2 (5.0 mCi). Efficacy analysis with earlier data cut-off dates for the same patients were previously presented at the 2026 ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium in January 2026 (ASCO-GI 2026) and the European Society for Medical Oncology Congress 2025 (ESMO 2025) in October 2025.

"Updated analyses continue to support the compelling overall clinical profile of [212Pb]VMT-α-NET as a treatment for GEP-NETs at the Cohort 2 dose level of 5 mCi per dose or up to 20 mCi cumulatively," said Markus Puhlmann, Chief Medical Officer of Perspective. "We are particularly encouraged by continued learning on the time to onset of best response, durability of response, as well as emerging long-term safety of [212Pb]VMT-α-NET. Meanwhile, we are enhancing our robust clinical package and adding optionality with additional dose cohorts, as well as looking beyond GEP-NETs."

As of the data cut-off date of March 4, 2026:

Safety findings based on 64 patients who received at least one treatment:

The 64 patients in this safety analysis comprised two patients in Cohort 1 (2.5 mCi), 46 patients in Cohort 2 (5.0 mCi), and 16 patients in Cohort 3 (6.0 mCi).
There were no reports of dose limiting toxicities (DLTs), treatment-related discontinuations, serious renal complications, dysphagia, or clinically significant treatment-related myelosuppression.
Grade 3 or higher treatment-emergent adverse events were reported in 23 patients (36%). One of these patients, who was enrolled in Cohort 3, experienced a transient lymphocyte count decrease on the cusp of Grades 3 and 4. This event was subsequently determined by the site to be a Grade 3 event. This event was transient and resolved without medical intervention. The patient completed the full course of [212Pb]VMT-α-NET treatment of four treatments without interruption and remains on study. No further Grade 4 events have occurred in this patient or in other patients in the study. There were no Grade 5 events.
No additional patients experienced serious adverse events (SAEs) since the most recent data update at ASCO (Free ASCO Whitepaper)-GI 2026, with none of the five SAEs deemed related to the study medication.

Anti-tumor activity based on both patients in Cohort 1 and 23 patients in Cohort 2:

Updated efficacy analysis in the same 25 patients from ASCO (Free ASCO Whitepaper)-GI 2026 and ESMO (Free ESMO Whitepaper) 2025 was presented with an additional ~12 weeks and ~25 weeks of follow-up, respectively.
18 of the 25 patients (72%) were without progression and remained alive, including both patients in Cohort 1.
Ten (43%) patients in Cohort 2 were observed to have response according to investigator-assessed RECIST v1.1. Nine of those responses were previously reported at ASCO (Free ASCO Whitepaper)-GI 2026, including one initial response reported at ASCO (Free ASCO Whitepaper)-GI 2026 that has since been confirmed. Since then, one more patient experienced an initial response in their most recent tumor assessment. As the patient remains on study, the patient is expected to receive a subsequent tumor assessment.
Eight (50%) of the 16 patients in Cohort 2 whose tumors all express SSTR2 were observed to have response according to investigator-assessed RECIST v1.1.
Nine patients were observed to have deepening of best response since initial tumor assessments on these patients were reported at ESMO (Free ESMO Whitepaper) in October 2025.
About [212Pb]VMT-α-NET

Perspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing somatostatin receptor type 2 (SSTR2). The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT).

(Press release, Perspective Therapeutics, APR 20, 2026, View Source [SID1234664591])

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

On April 20, 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, reported the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1 (CCNE1)-directed MGD, MRT-55811, to treat CCNE1-amplified solid tumors at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, being held April 17-22 in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"CCNE1 MGDs represent a first-in-class opportunity to directly target a frequently amplified driver oncogene in several solid tumor cancer populations with high unmet medical need. In CCNE1-amplified in vivo models of ovarian, gastric, and breast cancer, MRT-55811 demonstrated compelling monotherapy anti-tumor activity," said Sharon Townson, Ph.D., Chief Scientific Officer of Monte Rosa Therapeutics. "MRT-55811 also exhibited superior selectivity when compared to clinical-stage CDK2 inhibitors, suggesting that our CCNE1-directed MGDs could avoid the dose-limiting toxicities reported for these less selective agents. We believe that our oral CCNE1 degrader has the potential to provide clinical benefit across multiple cancer types where CCNE1 is amplified. These data also reinforce the power of our QuEEN discovery engine, as cyclin E1 represents yet another previously undruggable target we’ve successfully targeted. We anticipate submitting an IND for this program later this year."

The presentation, "Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers" (Abstract Presentation Number 6778), will be presented by Ralph Tiedt, Ph.D., Vice President, Biology, Monte Rosa Therapeutics, at the Minisymposium, "Targeted Protein Degradation and Non-canonical Oncogenic Signaling," on April 21, 2026, from 2:30 p.m. to 4:30 p.m. PT.

Summary of results:

MRT-55811 exhibited potent degradation and high selectivity for CCNE1, with no detectable degradation of closely related cyclins or cyclin-dependent kinases (CDKs), and favorable drug-like properties.
MRT-55811 induced deep cyclin E1 degradation and downstream pathway suppression, as well as co-degradation of CDK2 within the cyclin E1/CDK2 holoenzyme complex in CCNE1-amplified cell lines.
MRT-55811 demonstrated superior selectivity compared with clinical-stage CDK2 inhibitors, which exhibited significant off-target activity, as evidenced by kinome profiling and genetic modeling.
In CCNE1-amplified cancer cell lines, MRT-55811 selectively inhibited cellular proliferation, while sparing cell lines without amplification.
In vivo, MRT-55811 monotherapy resulted in tumor regression and pathway suppression in multiple CCNE1-amplified models.
MRT-55811 downmodulated retinoblastoma (RB) protein phosphorylation and E2F-driven gene expression, demonstrating on-target effects in tumors grown in vivo.

About CCNE1 MGDs
Cyclin E1 (CCNE1) is a well-recognized human oncogene and critical driver of cell cycle progression and cell proliferation and was historically considered an undruggable target. It acts as the regulatory subunit of the CCNE1-CDK2 holoenzyme, which coordinates G1-S cell cycle progression and drives cell proliferation through RB phosphorylation and repression. CCNE1 is frequently amplified or overexpressed across multiple cancer types, including ovarian, endometrial, gastric, breast, and others. Leveraging a cryptic pocket, Monte Rosa’s CCNE1-directed MGDs selectively degrade the cyclin E1/CDK2 holoenzyme complex, while sparing other proteins such as other closely related cyclins or CDKs. As a result of this exquisite selectivity, CCNE1-directed MGDs represent an opportunity to directly and selectively target a frequently amplified driver oncogene across multiple cancers.

(Press release, Monte Rosa Therapeutics, APR 20, 2026, View Source [SID1234664587])